Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

What is Novavax Inc.?

Novavax, Inc. (NVAX) is a biotechnology company with a key focus on vaccine development, notably the NVX-CoV2373 vaccine. Analysts believe there is potential for growth in the stock despite recent obstacles.

Why is Novavax Inc. going down?

NVAX stock is down 5.1% on Feb 5, 2026 19:47

• Novavax's stock showed a decline compared to the general market performance today.
• The drop in NVAX's stock value may be linked to the upcoming earnings report, which is anticipated to reveal negative earnings per share (EPS) and revenue numbers for the quarter.
• Despite the approval from the FDA for Novavax's COVID-19 vaccine, the stock encountered selling pressure, possibly due to profit-taking or market sentiment.
• The recent reevaluation of NVAX to a "sell" rating by Wall Street Zen could have also contributed to the downward trend, highlighting worries about the company's financial position and worth.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax, Inc. (NVAX) Stock Analysis: Assessing a 48% Potential Upside Amidst Market Challenges

Novavax, Inc. (NVAX) is a prominent biotechnology company focused on vaccine development, including its flagship NVX-CoV2373 vaccine. Despite challenges like negative free cash flow and revenue contraction, analysts project a potential 48% upside, with an average target price of $12.89. The stock is currently in oversold territory, and investors are advised to monitor strategic developments and regulatory milestones due to the speculative nature of the opportunity.

https://www.directorstalkinterviews.com/novavax-inc-nvax-stock-analysis-assessing-a-48-potential-upside-amidst-market-challenges/4121238101

Why Novavax (NVAX) Dipped More Than Broader Market Today

Novavax (NVAX) stock fell 3.68% to $8.37, underperforming the broader market indices like the S&P 500, Dow, and Nasdaq. The company is set to release its earnings, with analysts expecting an EPS of -$0.66 and revenue of $78.41 million for the upcoming quarter, along with significant annual growth predictions. Novavax currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics industry.

https://finance.yahoo.com/news/why-novavax-nvax-dipped-more-224504898.html

Novavax COVID-19 vaccine approved by the FDA

The article reports that the Novavax COVID-19 vaccine has received approval from the FDA. This indicates a new option for vaccination against the virus.

https://www.msn.com/en-us/health/other/novavax-covid-19-vaccine-approved-by-the-fda/ar-AA1EYw8W?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Assessing Novavax’s (NVAX) Valuation After Its New Matrix M Licensing Agreement With Pfizer

Novavax (NVAX) is experiencing renewed interest following a non-exclusive licensing agreement with Pfizer for its Matrix M adjuvant. Despite recent stock gains, long-term shareholders have faced significant losses. Analysts currently value NVAX as undervalued, with a consensus price target of $12.5, though this hinges on future regulatory and commercial milestones and sustained COVID vaccine demand.

https://www.sahmcapital.com/news/content/assessing-novavaxs-nvax-valuation-after-its-new-matrix-m-licensing-agreement-with-pfizer-2026-01-31

Novavax (NASDAQ:NVAX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen has downgraded Novavax (NASDAQ:NVAX) to a "sell" rating from a "hold." Despite mixed analyst ratings, the consensus remains "Hold" with an average price target of $11.25, while shares trade around $8.85. The company reported a Q4 EPS miss and high leverage, with a negative return on equity.

https://www.marketbeat.com/instant-alerts/novavax-nasdaqnvax-lowered-to-sell-rating-by-wall-street-zen-2026-01-31/

Trending Today

Estee Lauder Companies Inc. (The) ($EL) Stock Forecast: Down 18.7% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 13.6% Today

Cummins Inc. ($CMI) Stock Forecast: Down 11.0% Today

Qualys Inc. ($QLYS) Stock Forecast: Down 1.2% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 9.8% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 6.6% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 14.7% Today

Dogecoin ($DOGE) Crypto Forecast: Down 14.5% Today

Novavax Inc. Price History

30.00.2026 - NVAX Stock was down 5.3%

• Novavax's stock faced a downward trend despite the announcement of a licensing agreement with Pfizer for its Matrix-M adjuvant technology, which is viewed as a potential source of significant revenue.
• The decline in stock price may be linked to concerns regarding the company's core business in coronavirus vaccines, revenue inconsistencies, and challenges in internal vaccine development, as highlighted in recent discussions.
• There has been a notable increase in short interest and negative market sentiment towards Novavax, with a notably higher short interest compared to similar companies, potentially influencing the stock's downturn.
• Investors are awaiting Novavax's upcoming earnings report, anticipating a year-over-year decline in EPS and revenue, contributing to a cautious sentiment regarding the stock's future despite recent positive developments.

20.00.2026 - NVAX Stock was up 6.3%

• Novavax's upward movement today is linked to optimism surrounding its Matrix-M technology and strategic partnerships, discussed at a prominent healthcare conference.
• The company's shift towards partnership-focused strategies may have bolstered investor confidence in its future revenue growth potential.
• Concerns about Novavax's revenue generation and growth outlook persist despite the recent stock surge, influencing its price-to-sales ratio and market perception.
• Investors are closely watching Novavax's efforts to enhance its revenue metrics to validate the stock's substantial rise and sustenance of positive momentum in the long run.

28.00.2026 - NVAX Stock was down 5.1%

• The bearish movement in NVAX stock today may be attributed to concerns about the company's lack of growth prospects despite the recent surge in share price.
• The licensing agreement with Pfizer, though positive for industry validation and potential revenue streams, may not have been enough to offset investor worries about the company's future growth.
• The underperformance of NVAX compared to the broader market gains could have also contributed to the downward pressure on the stock today.
• Overall, the market sentiment towards NVAX seems to be cautious due to uncertainties surrounding its growth trajectory and revenue forecasts, leading to the bearish movement observed today.

28.00.2026 - NVAX Stock was down 5.1%

• The decline in NVAX stock today might be due to profit-taking following a recent rise in share price, along with concerns about the company's revenue forecast and growth outlook.
• While the collaboration with Pfizer is a positive step, it may not have been sufficient to maintain positive momentum, especially as some analysts have raised alerts about execution risks and potential revenue declines.
• The significant increase in the purchasing of call options suggests short-term optimism, but overall sentiment appears cautious due to the company's modest growth prospects.
• Investors are eagerly anticipating Novavax's forthcoming financial results, which are expected to reveal a decrease in EPS and revenue for the quarter, potentially exerting further downward pressure on the stock.

22.00.2026 - NVAX Stock was up 9.1%

• The bullish movement in NVAX today can be attributed to the significant licensing agreement with Pfizer, which includes upfront payment, potential milestones, and royalties, boosting investor confidence and leading to a surge in the stock price.
• The high volume of call options being bought indicates short-term bullish sentiment among traders, further driving up the stock price.
• Despite the positive news and reiterated "Buy" ratings from analysts, there are concerns about execution risks and revenue declines, leading to a divided opinion among analysts and hedge funds.
• While NVAX presents a unique opportunity in the vaccine market, the stock's volatility and speculative nature suggest that it may be more suitable for traders seeking short-term gains rather than long-term stability.

05.01.2026 - NVAX Stock was down 5.1%

• Novavax's stock showed a decline compared to the general market performance today.
• The drop in NVAX's stock value may be linked to the upcoming earnings report, which is anticipated to reveal negative earnings per share (EPS) and revenue numbers for the quarter.
• Despite the approval from the FDA for Novavax's COVID-19 vaccine, the stock encountered selling pressure, possibly due to profit-taking or market sentiment.
• The recent reevaluation of NVAX to a "sell" rating by Wall Street Zen could have also contributed to the downward trend, highlighting worries about the company's financial position and worth.

23.00.2026 - NVAX Stock was down 5.1%

• The recent 46% surge in Novavax's stock price sparked concerns over the company's growth potential, with analysts foreseeing a substantial revenue decline in contrast to industry trends. This disparity is likely driving the prevailing bearish sentiment surrounding NVAX.
• Despite a favorable non-exclusive licensing agreement with Pfizer and a rise in call options indicating short-term bullish sentiment, fears related to execution risks and revenue decreases are tempering overall investor confidence in Novavax.
• The significant deal with Pfizer, which involved a sizeable upfront payment and potential milestones, was initially well-received, leading to a stock price increase. However, uncertainties surrounding Novavax's growth path and financial prospects may be overshadowing the immediate advantages of the collaboration.
• Analyst perspectives on NVAX are divided, with some firms maintaining a "Buy" rating while others adjusting price targets downwards. This diverse outlook, combined with worries about the company's valuation and revenue projections, could be contributing to today's bearish market activity.

03.01.2026 - NVAX Stock was down 5.0%

• The FDA approval of Novavax's COVID-19 vaccine raised expectations, but the stock saw a downward trend, possibly due to profit-taking.
• Despite securing a licensing agreement with Pfizer for its Matrix M adjuvant, Wall Street Zen's downgrade to a "sell" rating caused stock pressure amid concerns about financial performance.
• BofA's increased price target and positive options activity generated some optimism. However, uncertainties over asset development timing under the license tempered investor enthusiasm.
• Pfizer's strategic collaborations with Novavax and other developments may have indirectly influenced Novavax's stock movement as investors reevaluated the pharmaceutical industry landscape.

14.00.2026 - NVAX Stock was down 5.2%

• Novavax's stock experienced a 6.1% decline, indicating subdued demand and negative investor sentiment.
• Factors contributing to this bearish trend include diminished revenue, an earnings per share (EPS) shortfall, and uninspiring revenue growth forecasts.
• Despite a noteworthy 11.1% stock rise on the back of COVID-19 vaccine trial outcomes, persistent financial challenges and the necessity for enhanced revenue generation have dampened overall investor confidence.
• The uptick in respiratory illnesses within the U.S. and Novavax's dedicated research and development (R&D) efforts for novel vaccines hold promise for future growth potential. However, investor wariness persists given the ongoing financial constraints and regulatory barriers.

14.00.2026 - NVAX Stock was down 5.1%

• Institutional investors may have engaged in profit-taking today on NVAX stock, possibly in response to recent gains offsetting a 4.2% rise with an 8.9% loss over the past year.
• Despite a stock increase of 11.1% driven by positive trial results for its updated COVID-19 vaccine, Novavax continues to grapple with challenges such as negative pretax profit margins and regulatory obstacles, contributing to the bearish sentiment.
• Novavax's strategic partnerships, cost reduction initiatives, and expansion beyond COVID-19 products have elicited a positive market response, with investors showing optimism about the company's long-term growth potential despite the recent bearish trend.

21.00.2026 - NVAX Stock was up 20.0%

• The rise in NVAX today is possibly linked to a new license agreement with Pfizer, indicating a temporary positive outlook among investors.
• Renewed support from BTIG, maintaining a "Buy" rating with a $19 price target, has bolstered confidence in NVAX's potential, despite differing analyst perspectives and adjustments from other companies.
• The CEO's focus on the success of the company's Matrix-M technology and growth strategy during the J.P. Morgan Healthcare Conference likely played a part in the favorable market movement, underscoring Novavax's standing in the global vaccine industry.
• Despite uncertainties regarding execution risks and revenue drops, the generally upbeat news related to NVAX's partnerships and vaccine technology appears to have eclipsed the cautious views, propelling the stock upwards.

21.00.2026 - NVAX Stock was up 9.5%

• BTIG's reaffirmation of a "Buy" rating and $19 price target for NVAX demonstrates that investors have confidence in the stock's potential, contributing to its strong uptrend.
• NVAX's emphasis on its Matrix-M technology, alliances with key partners, and efficient operational approach, as discussed in a recent healthcare conference, likely bolstered investor confidence.
• The company's transition to a partnership-centered strategy with profitability goals for 2028 through collaborations and expense management appears to have resonated positively with traders eyeing long-term growth prospects.
• Despite potential risks associated with NVAX, the market is evidently reacting favorably to the company's strategic moves and opportunities for market expansion through its vaccine portfolio and partnerships.